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Abstract
BACKGROUND: Hydroxychloroquine (HCQ) is used in the treatment of malaria and rheumatoid arthritis for a long 
time. Its effects on inflammation and immune modulation were noted. 
AIM: This study aims to investigate the effects of HCQ in fructose-induced metabolic syndrome and to explore its 
possible mechanisms.
METHODS AND MATERIALS: Sixty male Sprague-Dawley rats were divided into Group I (negative control), 
Group II fed on high-fructose diet, and Group III fed on high fructose and subdivided into Group III-a (HCQ 50 mg/kg), 
Group III-b (HCQ 100 mg/kg), Group III-c (HCQ 200 mg/kg), and Group III-d (metformin 100 mg/kg). Body weight, 
blood glucose, liver enzymes, and lipid profile were measured. Insulin level, homeostatic model assessment (HOMA), 
soluble-intercellular adhesion molecule, and vascular cell adhesion molecule were assayed. Tumor necrosis factor 
(TNF)-α, adipokines (leptin, resistin, and adiponectin), and histological examination of pancreas were assessed.
RESULTS: HCQ induces good effects on lipid profile and improves significantly HOMA, endothelial stress markers, 
and adiponectin, and reduces leptin and TNF-α levels. In addition, significant improvement in structural changes was 
noted in pancreas with different doses of HCQ.
CONCLUSION: Favorable effects of HCQ in fructose-induced metabolic syndrome are promising and can be used 
early in those at risk of diabetes.
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Introduction
Hydroxychloroquine (HCQ) is one of the 
famous antimalarial drugs, used also in rheumatic 
diseases due to its inflammatory and immune 
modulatory effects [1]. In diabetes mellitus, favorable 
effects were noted, but mechanisms are not well 
understood, and no previous experimental studies 
in metabolic syndrome induced by different agents 
had investigated its effect [2]. The observations of 
glucose-lowering side effects in non-diabetic patients 
have not been clarified yet, but mechanisms were 
suggested to explain the reduction in serum glucose 
levels such as increased insulin sensitivity as well 
as decreased insulin degradation [3]. Accordingly, in 
clinical scenarios, physicians should check glucose 
levels in the initial phase. Moreover, HCQ might be 
applied in rheumatic patients with refractory diabetes 
difficult to be controlled and rheumatics who are at risk 
to develop diabetes mellitus [4], [5].
Different adipokine plays a crucial role and 
represents the link between obesity and insulin 
resistance (IR). Disturbance in their levels explains 
largely the underlying mechanisms of metabolic 
syndrome and diabetes mellitus [6].
Metabolic syndrome is a group of multiple signs 
and symptoms. It largely increases the risk of diabetes 
mellitus and heart diseases. The metabolic syndrome 
consists of central obesity, hypertension, hyperglycemia, 
and dyslipidemia [7]. Early diagnosis of metabolic 
syndrome is a great step and the appropriate treatment 
can lower the risk of diabetes and cardiovascular disease 
and improve the patients’ long-term health [8], [9].
Metformin is one of the most commonly 
prescribed antidiabetic drugs. It is used as prophylactic 
therapy in subsets of metabolic syndrome to lessen risk of 
diabetes and to improve oxidative stress associated with 
it [10]. Metformin has a marvelous effect in reduction of 
intestinal absorption of glucose. Furthermore, it increases 
glucose uptake in the peripheral tissues, especially 
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muscle and adipocytes, and decreases hepatic glucose 
output. Hence, it improves lipid profile and vascular 
integrity and enhances weight reduction [11], [12].
We hypothesized that HCQ may have 
favorable effects on metabolic syndrome, so, the aim of 
the present work is to assess the protective role of HCQ 
with different therapeutic doses if any with comparison 
with reference drug and to elucidate the underlying 
mechanisms.
Chemicals
HCQ and metformin were obtained from Sigma 
(Sigma Chemical Co., St. Louis, MO, USA). High-fructose 
diet was from EL Nasr Pharmaceutical Chem Co., Egypt.
Animals
Sixty male Sprague-Dawley rats (12 weeks old, 
weighing 150–160 g) obtained from Mansoura, Faculty 
of Pharmacy, were used in the study. They were put 
under the same housing conditions. Rats were housed 
in a temperature-controlled room under 12 h light/dark 
conditions and get ad libitum food and water. All animal 
experiments were conducted according to the Guide for 
the Care and Use of Laboratory Animals prepared by 
Mansoura Medical Research Ethics Committee, Egypt, 
Code Number R/17.12.181.
Design of the work
After acclimatization, the rats were randomly 
allocated into six groups (10 for each):
Group I:  Negative control (n = 10) fed on a normal diet 
for 8 weeks and received a normal saline for 
4 weeks.
Group II:  Fed on a high-fructose diet (60% fructose) for 
8 weeks (n = 10) and received a normal saline 
for 4 weeks [13].
Group III:  Fed on high-fructose diet (60% fructose) 
for 8 weeks (n = 40), then it was subdivided 
randomly into four equal groups (n = 10):
• Group III-a received HCQ 50 mg/kg once 
daily for 4 weeks
• Group III-b received HCQ 100 mg/kg once 
daily for 4 weeks [14].
• Group III-c received HCQ 200 mg/kg once 
daily for 4 weeks [14].
• Group III-d received metformin (100 mg/kg) 
once daily for 4 weeks [15].
Parameters of the study
Body weight was measured at the start and 
end of the experiment.
Plasma glucose level was assessed by 
enzymatic method according to Trinder (1969) [16] 
using glucose kits (BioMed-Glucose, Hannover, 
Germany) according to the manufacture instruction.
Insulin was measured by ELISA kits according 
to the manufacture (DRG International, Inc., New 
Jersey, USA).
Fasting leptin was determined by ELISA (Linco 
Research Inc., St. Louis, MO, USA). Furthermore, 
resistin (Abcam’s Rat ELISA) was measured.
Cholesterol was assessed by enzymatic 
colorimetric method according to Trinder (1969) [16] 
using cholesterol kits (BioMed-Cholesterol, Hannover, 
Germany) according to the manufacture instruction.
Plasma high-density lipoprotein cholesterol 
(HDL-C) level was measured by enzymatic colorimetric 
method according to Tietz (1976) [17] using HDL-C 
kits (BioMed-HDL-C, Eng. Chem. for lab technology, 
Hannover, Germany) according to the manufacture 
instruction.
Plasma triglycerides (TGs) level was determined 
by enzymatic colorimetric method according to Fossati and 
Principe (1982) [18] using TGs kits (BioMed-Triglycerides 
L.S, Eng. Chem. for lab technology, Hannover, Germany) 
according to the manufacture instruction.
Plasma low-density lipoprotein cholesterol 
(LDL-C) level was determined according to Tietz 
(1976) [17] from equation:
LDL-C (mg/dl) = Total 
cholesterol - (Triglycerides ÷ 5) - HDL-C.
Serum alanine transaminase (ALT) level was 
determined by enzymatic colorimetric method according 
to Tietz (1976) [17] using ALT kits (BioMed-ALT, 
Eng. Chem. for lab technology, Hannover, Germany) 
according to the manufacture instruction.
Serum aspartate transaminase (AST) level 
was determined by enzymatic colorimetric method 
according to Tietz (1976) [17] using AST kits (BioMed-
AST, Eng. Chem. for lab technology, Hannover, 
Germany) according to the manufacture instruction.
Adiponectin
It was analyzed using RayBio Adiponectin 
ELISA Kit (RayBiotech, Inc., USA), used for quantitative 
measurement of adiponectin in serum of rat depending 
on the principle of competitive enzyme immunoassay.
Tumor necrosis factor (TNF)-α
TNF-α (Ray Bio_ Rat TNF-alpha ELISA Kit 
Protocol) (Cat#: ELR TNF alpha-001). It was analyzed 
using Ray Bio TNF-alpha ELISA Kit (RayBiotech, Inc., 
USA), used for quantitative measurement of TNF-alpha 
in serum of rat.
Soluble intercellular adhesion molecule-1 
(sICAM-1), soluble vascular cell adhesion molecule 
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(sVCAM-1) are estimated by ELISA according to 
manufacture instruction.
Homeostasis model assessment of IR 
was measured by homeostatic model assessment 
(HOMA) = (fasting plasma insulin × fasting plasma 
glucose) ÷ 22.5; when glucose in mmol/l and insulin in 
ut/ml [19]. IR was considered when HOMA >2.6 [20].
Histological procedure
Immediately after resection of pancreas, it was 
fixated in 10% formalin solution. The paraffin blocks 
were cut at 4–5 ml thickness. In a blindfold manner, 
all histological evaluations were performed by a light 
microscope mounted to digital camera connected to 
a computer. The presence of cellular injury, such as 
inflammation or fibrosis, was evaluated. In addition, islet 
size and the amount of fat in the pancreatic tissue were 
examined using H and E (H and E)-stained slides. The 
paraffin sections of pancreatic tissue were stained with H 
and E after removing paraffin. Under optical microscope, 
the histopathological evaluation was performed by a 
pathologist who was blind with the animal grouping.
Exocrine pancreatic damage was assessed 
as regard to the presence of congestion, fibrosis, 
and inflammatory infiltrate in the interstitial tissues 
and graded by semi-quantitative method ranging 
from 0 (minimal) to 3 (severe and extensive damage) 
according to the presence of inflammatory infiltrate, 
congestion, vacuolization, and fibrosis, and considering 
the entire exocrine parenchyma on the slide. Islets of 
Langerhans (IOL) changes including islet shape, intra-
islet congestion, inflammatory infiltrate, fibrosis, and 
vacuolization were evaluated [21].
Statistical analysis
The data were expressed as mean ± standard 
deviation (SD). Data were processed and analyzed using 
the SPSS version 10.0 (SPSS, Inc., Chicago, Ill., USA). 
One-way ANOVA was done followed by Tukey’s post hoc 
test. Results were considered significant if p ≤ 0.05.
Results
In Table 1, in the present study, HCQ at its 
different doses (Group III a, b, and c) exerts insignificant 
reduction of body weight (p > 0.05) when compared 
to Group II, this effect is also seen with Group III-d. In 
addition, there were a little insignificant effect of tested 
drugs either HCQ or thiazide on glucose and insulin levels 
when compared to Group II (p > 0.05). Nonetheless, the 
effects of tested drugs are more significant as regard 
HOMA when compared to Group II (p < 0.05).
In Table 2, there was significant reduction of 
cholesterol levels in all tested drugs and significant up 
increase of HDL of all tested drugs when they compared 
to Group II (p < 0.05). However, these changes were 
insignificant as regard TG and LDL (p > 0.05).
Table 2: Effect of different doses of HCQ and thiazide on 
cholesterol, HDL, TG, and LDL (Mean±SD)
Groups Cholesterol (mg/dl) HDL (mg/dl) TG (mg/dl) LDL (mg/dl)
Group I 130.13 ± 4.1 57 ± 2.8 158.5 ± 5.86 76 ± 6.3
Group II 212.88 ± 5.4* 33.88 ± 5.9* 178.9 ± 2.8* 113.3 ± 6*
Group III-a 180.63 ± 10.14*,# 41.25 ± 5.03*,$ 170.88 ± 5.69* 108.13 ± 4.01*
Group III-b 177.75 ± 6.25*,# 42.13 ± 3.64*,# 174.5 ± 4.81* 107.5 ± 4.75*
Group III-c 178 ± 6.7*,# 45.13 ± 4.42*,# 176.25 ± 3.85* 106.4 ± 3.4*
Group III-d 172.5 ± 4.5*,# 48.5 ± 3.82*,# 176.3 ± 5.6* 109.75 ± 6.6*
*Significance of other groups versus Group I, #Significance of other groups versus Group II, $Significance 
of other groups versus Group III-d. HCQ: Hydroxychloroquine, HDL: High-density lipoprotein, LDL: Low-
density lipoprotein, TG: Triglyceride.
In Table 3, all tested drugs have insignificant 
reduction of liver enzymes as they compared to Group II 
(p > 0.05).
Table 3: Effect of different doses of HCQ and thiazide on liver 
enzymes AST and ALT (Mean±SD)
Groups AST (units/l) ALT (units/l)
Group I 22.75 ± 3.45 24.38 ± 2.1
Group II 48.25 ± 2.5* 51 ± 5.4*
Group III-a 46.88 ± 2.8* 50.4 ± 2.9*
Group III-b 47.13 ± 2.6* 49.9 ± 2.6*
Group III-c 46 ± 3.4* 48.25 ± 3.05*
Group III-d 44.75 ± 5.6*,# 48.8 ± 2.9*
HCQ: Hydroxychloroquine, ALT: Alanine transaminase, AST: Aspartate transaminase.
In Table 4, all medications were able to exert 
significant reduction of TNF-α, ICAM, and VCAM when 
compared to Group II (p < 0.05).
Table 4: Effect of different doses of HCQ and thiazide on 
markers of inflammation (TNF-α, soluble ICAMs, and VCAM) 
(Mean±SD)
Groups TNF-α (ng/ml) ICAM (ng/ml) VCAM (ng/ml)
Group I 2.59 ± 0.24 111.63 ± 8.1 150.5 ± 7.9
Group II 6.5 ± 0.51*,# 221.6 ± 13.98* 187 ± 5.04*
Group III-a 5.7 ± 0.55*,#,$ 181.38 ± 8.48*,# 173.25 ± 6.5*,#
Group III-b 4.9 ± 0.25*,# 178.63 ± 7.87*,# 172.75 ± 6.4*,#
Group III-c 4.6 ± 0.31*,# 182.38 ± 8.2*,# 171.25 ± 10.6*,#
Group III-d 4.7 ± 0.39*,# 179 ± 8.4*,# 172 ± 8.6*,#
*Significance of other groups versus Group I, #Significance of other groups versus Group II, $Significance 
of other groups versus Group III-d. HCQ: Hydroxychloroquine, ICAM: Intercellular adhesion molecule, 
VCAM: Vascular cell adhesion molecule, TNF: Tumor necrosis factor.
In Table 5, HCQ at its different doses beside 
thiazide decreases significantly leptin when compared 
with positive control group (p < 0.05) with insignificant 
reduction in resistin levels (p > 0.05). As regard 
adiponectin, all medications given to rats significantly 
increase it when compared to Group II (p > 0.05).
Table 1: Effect of different doses of HCQ and thiazide on body 
weight, glucose, insulin, and HOMA (Mean±SD)
Groups Body weight g Glucose (mmol/l) Insulin (uU/ml) HOMA
Group I 172.25 ± 8.9 5.4 ± 0.42 5.5 ± 0.93 1.4 ± 0.1
Group II 183.2 ± 7.04* 7.12 ± 1.24* 7.25 ± 1.03* 2.61 ± 0.06*
Group III-a 178.75 ± 4.8 6.3 ± 1.3 7.4 ± 1.06* 2.02 ± 0.12*,#,$
Group III-b 180 ± 5.01 6.3 ± 1.03 7.5 ± 1.1* 2 ± 0.12*,#,$
Group III-c 177.75 ± 4.37 6.6 ± 1.4 7.75 ± 0.7* 1.98 ± 0.16*,#,$
Group III-d 176.5 ± 4.21 6.4 ± 1.1 7.25 ± 0.9* 1.73 ± 0.07*,#
*Significance of other groups versus Group I, #Significance of other groups versus Group II, $Significance of 
other groups versus Group III-d. HCQ: Hydroxychloroquine, HOMA: Homeostatic model assessment.
Table 5: Effect of different doses of HCQ and thiazide on 
adipokines (leptin, resistin, and adiponectin) (Mean ±SD)
Groups Leptin (ng/ml) Resistin (ng/ml) Adiponectin (ng/ml)
Group I 20.4 ± 2.97 7.62 ± 1.4 68.3 ± 3.96
Group II 30.75 ± 3.7* 26.88 ± 3.4* 44.8 ± 6.4*
Group III-a 19 ± 2.7# 22.75 ± 2.4* 57.4 ± 3.3*,#
Group III-b 18.25 ± 2.6# 22.4 ± 3.5* 60 ± 3.2*,#
Group III-c 18.12 ± 2.4# 23 ± 3.9* 61.13 ± 3.3*,#
Group III-d 17.5 ± 1.85# 23.4 ± 3.5* 60.5 ± 3.9*,#
HCQ: Hydroxychloroquine. *p<0.003, #p<0.001  
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Histological results
The typical view of the IOL was seen in the 
control group. They were formed of anastomosing 
cords of epithelial cells surrounded by the exocrine 
pancreatic acini (Figure 1). The IOL was disrupted in 
Group II. In many cells, cytoplasm was heterogeneous 
and vacuolated along with hyperchromatic enlarged 
nuclei which occasionally disappeared in some cells. 
In addition, the matrix between the cells was infiltrated 
by mononuclear cell infiltrate mostly at the periphery of 
the islets and widened by hyaline deposition (Figure 2). 
Almost all the cellular components of the IOL were intact 
with minimal hyaline deposition of the matrix and nearly 
absent inflammatory cells in all HCQ-treated groups 
(200, 100, and 50 mg, respectively) when compared with 
Group II. Furthermore, less evident histopathological 
changes were detected HCQ-treated groups in a dose of 
200 mg than HCQ-treated groups in a doses of 100 mg 
and 50 mg (Figures 3-5).
Figure 1: Group 1 (normal control, received 0.5 ml of saline): The islet 
cells are embedded in normal proportions of the acinar cells that are 
arranged in lobules (H and E, ×100).
In the group treated with metformin (Figure 6), preservation 
of the IOL structure was seen to a wide degree.
Figure 2: Group II shows mild lymphocytic infiltrate with eosinophilic 
material in the islets (H and E, ×400)
Discussion
Metabolic syndrome is a collection of metabolic 
changes such as hypertension, hyperglycemia, 
abdominal obesity, dyslipidemia, and IR. It increased 
gradually over recent years causing high morbidity 
and mortality [7], [22]. HCQ is widely used drugs in 
rheumatic diseases and control of malaria. All previous 
studies discussing only the role of HCQ in the treatment 
of diabetes that is associated with rheumatic diseases 
and occur secondary to it. No other studies evaluate 
the prophylactic role of HCQ in risky patients that may 
develop metabolic diseases like diabetes. In the present
Figure 3: Group III-a (get hydroxychloroquine orally at a dose 
of 50 mg/kg/week): Moderate lymphocytic infiltrate with evident 
vacuolization of the acinar cells (H and E, ×400)
 study, HCQ exerts an ameliorating effect on lipid profile 
as regard reduction of cholesterol and elevation of HDL. 
Furthermore, HCQ improves significantly endothelial 
stress markers and adiponectin and reduces leptin 
and TNF-α levels. In addition, significant improvement 
in structural changes was noted in pancreas with 
different doses of HCQ. Those findings are in
 
Figure 4: Group III-b (get hydroxychloroquine orally at a dose of 
100 mg/kg): Mild lymphocytic infiltrate in and around the islets with 
scattered normal islet cells (H and E, ×400)
consistent with other studies which hold that HCQ 
possibly produces a favorable outcome, may be partly 
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related to its effects on endothelial stress markers as 
well as adipokines that usually altered in the presence 
of IR which considered as initial events in metabolic 
syndrome. HCQ can augment insulin action through 
enhancement of its binding to the receptors in different 
organs that characterized by initial development of 
resistance in metabolic syndrome and these events 
open the way to diabetes later on. In the same way, it 
alters hepatic metabolism of insulin [23].
Figure 6: Group III-d (metformin-treated group 100 mg/kg orally): The 
IOL structure was preserved with intact cellular component, nearly 
absent inflammatory cells and minimal hyaline deposition (H and E, 
×400)
Some studies point that HCQ may have 
therapeutic potential in the treatment of type I and type II 
diabetes. It significantly raised the blood concentration 
of insulin. This observation may be supported that it 
may inhibit cytosolic insulin metabolizing enzymes 
and minimize its degradation [24]. In the same line, 
other studies document the beneficial impact of HCQ 
in correction of different adipokines levels such as 
leptin, adiponectin, and significant reduction of the 
vascular endothelial stress markers such as sICAM and 
sVICAM [25], [26].
Large body of evidence demonstrating a 
beneficial role of HCQ in amelioration of lipid profile is 
present. This effect can be attributed to upregulation 
of lipid receptors and its immune modulatory 
effects [27]. On the contrary, other studies do not 
exhibit any positive changes in lipid profile during HCQ 
treatment [28], [29], [30].
In diabetes, the clearance of HCQ significantly 
increases either through renal and non-renal routes [31] 
that will affect HCQ levels in this category of patients. 
However, HCQ exhibits good impacts on the histological 
and the metabolic profiles in diabetic patients. Those 
effects may be partly attributed to its anti-inflammatory 
action and immune modulation [25].
Anti-inflammatory effects of HCQ extend to 
other tissues. In addition, it plays an important role as 
antiproliferative. This effect may be related to regulation 
of pro-inflammatory cytokines expression such as TNF-α 
and inhibition of NF-κB phosphorylation. It also reduces 
inflammatory neutrophils infiltration. It significantly 
ameliorates fibrosis in rats with bleomycin-induced 
pulmonary fibrosis. It inhibits the rat lung fibroblasts 
proliferation and regulates inflammation [32]. HCQ 
reduces the expression of connective tissue growth 
factor and phosphorylation of extracellular regulated 
protein kinase (p-ERK) and upregulate Beclin-1, a key 
regulator of autophagy [33].
The molecular effects of HCQ can target 
many subcellular organelles. It prevented the TNF-α-
induced translocation of NF-κB p65 into the nucleus 
and the phosphorylation of the p65 subunit. It inhibited 
the expression of phosphorylated p38 and JNK 
protein [34]. Furthermore, it substantially reduced TNF-
α-induced endothelial-leukocyte adhesion and the 
leukocyte transmigration in pulmonary interstitial tissue. 
Furthermore, it dramatically inhibited the expression of 
TNF-α-induced endothelial ICAM-1 and VCAM-1 [34].
In other studies, HCQ was studied to relate 
its effects on neutrophil that plays an important role in 
inflammation and tissue damage. The authors found 
that HCQ reduced neutrophil-derived oxidants [35].
HCQ plays an important role in the mitigation 
of fibrosis and tissue remodeling. It promotes a 
preconditioning like protection in an in vivo simulated 
rat myocardial ischemia reperfusion injury model 
through enhancing of phosphorylation of the pro-survival 
kinase ERK1/2 [36]. It is protective through enhanced 
phosphorylation of the pro-survival kinase ERK1/2 [36]. It 
efficiently inhibited hepatic cystogenesis in the polycystic 
kidney disease and affected the autophagy process 
that increased in polycystic liver disease [37]. HCQ is 
evaluated in cardiac neonatal lupus model and it gives 
favorable results. The authors ascribe this effect due to its 
effects on diminishing an inflammatory component [38].
Conclusion
This favorable improvement of metabolic 
syndrome by HCQ due to the improvement of lipid 
profile and adipokines and structural changes in the 
pancreas pays our attention to make more human 
Figure 5: Group III-c (get hydroxychloroquine orally at a dose of 
200 mg/kg): Small-sized islet cells and scattered lymphocytic infiltrate 
in the islets surrounded by normal acinar cells (H and E, ×400)
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studies to consider HCQ as a potential drug in patients 
who are at risk of metabolic syndrome, particularly at 
low doses. This promising effects of HCQ can minimize 
cardiovascular risk in large categories of patients.
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